Strategic biotech investor RTW Investments is a life sciences focused investment firm with active venture, growth, and public market participation across the biotech ecosystem, presenting opportunities for collaboration, deal sourcing, and co-investments aligned with portfolio companies.

Global presence With headquarters in New York and offices in London and Shanghai, RTW offers cross-border reach and regional engagement potential, making them a strong partner for international clinical programs, regulatory navigation, and global financing solutions.

Recent financing activity RTW has recently led or participated in multiple significant biotech financings, including a $50M Series A for Prolium Bio and a $165M crossover for Windward Bio, signaling readiness for large syndicated deals and scalable portfolio opportunities.

Partnership potential RTW engages in strategic partnerships such as royalty funding with Candel Therapeutics and private placements with Tenax Therapeutics, indicating openness to alternative financings and structured deals that can be modeled for other biotech clients.

Talent and capabilities RTW has expanded leadership in human resources with a dedicated MD/Head of HR and leverages a modern tech stack for deal flow and operations, suggesting capacity to onboard and support portfolio founders, executives, and corporate partnerships efficiently.